Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440869 | 0.74 | DYRK1A (0.49) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 | |
| SCHEMBL405358 | 0.72 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PCSK9PIK3CD | |
| SCHEMBL2750457 | 0.72 | TGFBR1 (0.51) | DYRK1ASCN5ATGFBR1PCSK9PIK3CD | |
| SCHEMBL4162933 | 0.72 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 | |
| SCHEMBL30512173 | 0.72 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 | |
| SCHEMBL4789377 | 0.72 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 | |
| SCHEMBL23529908 | 0.68 | DYRK1A (0.44) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 | |
| SCHEMBL3162678 | 0.68 | DYRK1A (0.65) | DYRK1ASCN5ATGFBR1PIK3CD | |
| SCHEMBL7851567 | 0.68 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PCSK9PIK3CD | |
| SCHEMBL29984317 | 0.68 | DYRK1A (0.44) | DYRK1ASCN5ATGFBR1NAMPTPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3439663-B1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3699181-B1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | ARRAY BIOPHARMA INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11484535-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | LOXO ONCOLOGY, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11191766-B2 | Methods of treating pediatric cancers | LOXO ONCOLOGY, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3218380-B1 | PREPARATION OF A CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | ARRAY BIOPHARMA INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200338079-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2020-10-29 | — | — | US | disclosed |
| US-10813936-B2 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | ARRAY BIOPHARMA, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10799505-B2 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | ARRAY BIOPHARMA, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3699181-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | Array Biopharma, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200237765-A1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| EP-3218380-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | Array Biopharma, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170165267-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | ARRAY BIOPHARMA, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2016077841-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | ARRAY BIOPHARMA, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137654-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | ARRAY BIOPHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | SCN5A 2290/4885DYRK1A 90/4885TGFBR1 1184/4885 |
| US-10813936-B2 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | SNCA, SFPQ, PYCR1 | SCN5A 14/4885DYRK1A 1715/4885TGFBR1 2951/4885 |
| US-11191766-B2 | Methods of treating pediatric cancers | VHL, HDAC6, PAICS | SCN5A 1031/4885DYRK1A 2667/4885TGFBR1 4704/4885 |
| US-20160137654-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | SNCA, SFPQ, PYCR1 | SCN5A 14/4885DYRK1A 1715/4885TGFBR1 2951/4885 |
| US-20200338079-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | SCN5A 297/4885DYRK1A 1116/4885TGFBR1 4559/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | SCN5A 2290/4885DYRK1A 90/4885TGFBR1 1184/4885 |
| US-20200237765-A1 | METHODS OF TREATING PEDIATRIC CANCERS | VHL, HDAC6, PAICS | SCN5A 1031/4885DYRK1A 2667/4885TGFBR1 4704/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | SCN5A 2290/4885DYRK1A 90/4885TGFBR1 1184/4885 |
| US-11484535-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | IL5, IL1A, RRP15 | SCN5A 297/4885DYRK1A 1116/4885TGFBR1 4559/4885 |
| US-10799505-B2 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | SNCA, SFPQ, PYCR1 | SCN5A 20/4885DYRK1A 1707/4885TGFBR1 3074/4885 |
| US-20170165267-A1 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | SNCA, SFPQ, PYCR1 | SCN5A 14/4885DYRK1A 1715/4885TGFBR1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.